News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fraunhofer USA Center for Molecular Biotechnology Begins Clinical Trial Of New Malaria Vaccine Approach


2/5/2014 5:41:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Del.--(BUSINESS WIRE)--Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer’s plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study. Antibodies directed at Pfs25 can block transmission of the malaria parasite from mosquitoes to humans by preventing the parasite from developing in the mosquito. In preclinical models, purified plant-derived virus-like particles containing Pfs25, in combination with the adjuvant Alhydrogel®, have been shown to induce antibodies that effectively block infection of mosquitoes that have fed on an infectious blood meal. If these results can be reproduced in humans, the vaccine approach may provide a strategy to interrupt malaria transmission and thereby contribute to reduction of the P. falciparum disease burden.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Malaria

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES